Literature DB >> 32119072

Breeze: an integrated quality control and data analysis application for high-throughput drug screening.

Swapnil Potdar1, Aleksandr Ianevski1,2, John-Patrick Mpindi1, Dmitrii Bychkov1, Clément Fiere1, Philipp Ianevski1, Bhagwan Yadav1, Krister Wennerberg1,3, Tero Aittokallio1,2,4, Olli Kallioniemi1,5, Jani Saarela1, Päivi Östling1,5.   

Abstract

SUMMARY: High-throughput screening (HTS) enables systematic testing of thousands of chemical compounds for potential use as investigational and therapeutic agents. HTS experiments are often conducted in multi-well plates that inherently bear technical and experimental sources of error. Thus, HTS data processing requires the use of robust quality control procedures before analysis and interpretation. Here, we have implemented an open-source analysis application, Breeze, an integrated quality control and data analysis application for HTS data. Furthermore, Breeze enables a reliable way to identify individual drug sensitivity and resistance patterns in cell lines or patient-derived samples for functional precision medicine applications. The Breeze application provides a complete solution for data quality assessment, dose-response curve fitting and quantification of the drug responses along with interactive visualization of the results.
AVAILABILITY AND IMPLEMENTATION: The Breeze application with video tutorial and technical documentation is accessible at https://breeze.fimm.fi; the R source code is publicly available at https://github.com/potdarswapnil/Breeze under GNU General Public License v3.0. CONTACT: swapnil.potdar@helsinki.fi. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
© The Author(s) 2020. Published by Oxford University Press.

Entities:  

Year:  2020        PMID: 32119072     DOI: 10.1093/bioinformatics/btaa138

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  19 in total

1.  Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells.

Authors:  Elina Parri; Heikki Kuusanmäki; Daria Bulanova; Satu Mustjoki; Krister Wennerberg
Journal:  Blood Adv       Date:  2021-04-13

2.  DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs).

Authors:  Aleksandr Ianevski; Ronja M Simonsen; Vegard Myhre; Tanel Tenson; Valentyn Oksenych; Magnar Bjørås; Denis E Kainov
Journal:  Nucleic Acids Res       Date:  2022-05-24       Impact factor: 19.160

3.  Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma.

Authors:  Sonja Krausert; Sebastian Brabetz; Norman L Mack; Felix Schmitt-Hoffner; Benjamin Schwalm; Heike Peterziel; Aileen Mangang; Tim Holland-Letz; Laura Sieber; Andrey Korshunov; Ina Oehme; Natalie Jäger; Olaf Witt; Stefan M Pfister; Marcel Kool
Journal:  Neurooncol Adv       Date:  2022-03-13

4.  High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma.

Authors:  Katja Tuomainen; Aini Hyytiäinen; Ahmed Al-Samadi; Philipp Ianevski; Aleksandr Ianevski; Swapnil Potdar; Laura Turunen; Jani Saarela; Sergey Kuznetsov; Wafa Wahbi; Maija Risteli; Antti Mäkitie; Outi Monni; Tuula Salo
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

5.  Comprehensive and unbiased multiparameter high-throughput screening by compaRe finds effective and subtle drug responses in AML models.

Authors:  Morteza Chalabi Hajkarim; Ella Karjalainen; Mikhail Osipovitch; Konstantinos Dimopoulos; Sandra L Gordon; Francesca Ambri; Kasper Dindler Rasmussen; Kirsten Grønbæk; Kristian Helin; Krister Wennerberg; Kyoung-Jae Won
Journal:  Elife       Date:  2022-02-15       Impact factor: 8.713

6.  Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections.

Authors:  Aleksandr Ianevski; Rouan Yao; Eva Zusinaite; Laura Sandra Lello; Sainan Wang; Eunji Jo; Jaewon Yang; Erlend Ravlo; Wei Wang; Hilde Lysvand; Kirsti Løseth; Valentyn Oksenych; Tanel Tenson; Marc P Windisch; Minna M Poranen; Anni I Nieminen; Svein Arne Nordbø; Mona Høysæter Fenstad; Gunnveig Grødeland; Pål Aukrust; Marius Trøseid; Anu Kantele; Eglė Lastauskienė; Astra Vitkauskienė; Nicolas Legrand; Andres Merits; Magnar Bjørås; Denis E Kainov
Journal:  Viruses       Date:  2021-12-11       Impact factor: 5.048

7.  Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics.

Authors:  Cristina E Tognon; Rosalie C Sears; Gordon B Mills; Joe W Gray; Jeffrey W Tyner
Journal:  Annu Rev Cancer Biol       Date:  2020-12-08

8.  A Covalent Calmodulin Inhibitor as a Tool to Study Cellular Mechanisms of K-Ras-Driven Stemness.

Authors:  Sunday Okutachi; Ganesh Babu Manoharan; Alexandros Kiriazis; Christina Laurini; Marie Catillon; Frank McCormick; Jari Yli-Kauhaluoma; Daniel Abankwa
Journal:  Front Cell Dev Biol       Date:  2021-07-08

9.  Identification of novel regulators of STAT3 activity.

Authors:  Elina Parri; Heikki Kuusanmäki; Arjan J van Adrichem; Meri Kaustio; Krister Wennerberg
Journal:  PLoS One       Date:  2020-03-31       Impact factor: 3.240

10.  High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro.

Authors:  Laura Torrente; Gunjit Maan; Asma Oumkaltoum Rezig; Jean Quinn; Angus Jackson; Andrea Grilli; Laura Casares; Ying Zhang; Evgeny Kulesskiy; Jani Saarela; Silvio Bicciato; Joanne Edwards; Albena T Dinkova-Kostova; Laureano de la Vega
Journal:  Biomolecules       Date:  2020-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.